Investigational drug · Phase 2
BBT-207
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for EGFR Mutant Advanced Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BBT-207"
First trial start
2023
Sep 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BBT-207", any sponsor or status.
Conditions studied
As listed on its trial records.
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BBT-207" as an intervention, largest first.
- First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIActive, not recruiting
Bridge Biotherapeutics, Inc.Industry
NCT05920135 · 24 participants · Start Sep 11, 2023 · Primary completion Aug 1, 2026
Drug: BBT-207 · For: EGFR Mutant Advanced Non-Small Cell Lung Cancer
Sites: Seongnam-si, South Korea; Seoul, South Korea · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Gawli CS, Patil CR, Patel HM · Bioorg Med Chem 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.